Penumbra (PEN) Free Cash Flow Growth (3y) (2017 - 2026)
Penumbra (PEN) Free Cash Flow Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.92 Bn | 146.27 Bn | 6.27 Bn | 6.28% |
| 2 | Stryker | 119.50 Bn | 116.62 Bn | 3.81 Bn | 9.63% |
| 3 | Medtronic | 102.71 Bn | 94.54 Bn | 5.76 Bn | 22.80% |
| 4 | Boston Scientific | 69.72 Bn | 68.51 Bn | 3.61 Bn | 29.36% |
| 5 | Edwards Lifesciences | 49.24 Bn | 45.57 Bn | 1.29 Bn | -27.72% |
| 6 | GE HealthCare Technologies | 29.74 Bn | 27.67 Bn | 1.98 Bn | -20.37% |
| 7 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | -0.27% |
| 8 | Dexcom | 28.96 Bn | 27.84 Bn | 750.30 Mn | 77.20% |
| 9 | Steris | 20.31 Bn | 19.88 Bn | 697.10 Mn | 19.32% |
| 10 | Penumbra | 12.51 Bn | 11.90 Bn | 253.41 Mn | 99.48% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 99.48% |
| Dec 31, 2025 | 239.66% |
| Sep 30, 2025 | 86.18% |
| Jun 30, 2025 | 38.68% |
| Mar 31, 2025 | 79.14% |
| Dec 31, 2024 | 65.57% |
| Sep 30, 2024 | 14.66% |
| Jun 30, 2024 | 94.66% |
| Mar 31, 2024 | 58.23% |
| Dec 31, 2023 | 194.89% |
| Sep 30, 2023 | 20.75% |
| Jun 30, 2023 | 39.03% |
| Mar 31, 2023 | 37.07% |
| Dec 31, 2022 | -35.08% |
| Sep 30, 2022 | -43.31% |
| Jun 30, 2022 | -217.07% |
| Mar 31, 2022 | -47.89% |
| Dec 31, 2021 | -73.84% |
| Sep 30, 2021 | 49.19% |
| Jun 30, 2021 | -80.15% |